

Supplementary Table 1. Baseline characteristics from the secondary outcome (n =597)

Characteristic	Derivation cohort	Validation cohort	p-value
Demographics			
No. of patients	517 (86.6)	80 (13.4)	
Age (yr)	42.5 ± 13.2	39.1 ± 13.4	0.03
Female sex	308 (59.6)	46 (57.5)	0.82
SBP (mmHg)	133.6 ± 18.8	128.3 ± 17.6	0.02
DBP (mmHg)	86.1 ± 12.4	83.9 ± 12.5	0.14
Pulse pressure (mmHg)	77.4 ± 12.4	78.5 ± 10.2	0.47
Body mass index (kg/m ²)	24.2 ± 4.5	24.2 ± 4.0	0.93
Alcohol			
Current	178 (34.4)	26 (32.5)	
Past	44 (8.5)	6 (7.5)	
Never	279 (54.0)	47 (58.8)	
Smoking			
Current	68 (13.2)	5 (6.3)	0.20
Past	48 (9.3)	9 (11.3)	
Never	395 (76.4)	65 (81.3)	
Past history			
Hypertension	208 (40.2)	32 (40.0)	0.73
Diabetes mellitus	24 (4.6)	3 (3.8)	>0.99
Symptoms and signs at biopsy			
Edema	18 (3.5)	2 (2.5)	>0.99
Gross hematuria	24 (4.6)	3 (3.8)	0.05
Oxford classification			
Mesangial (M) 1	144 (27.9)	16 (20.0)	0.17
Endocapillary (E) 1	136 (26.3)	23 (28.8)	0.74
Glomerular sclerosis (S) 1	375 (72.5)	63 (78.8)	0.52
Tubulointerstitial damage (T) 1	74 (14.3)	18 (22.5)	0.01
Tubulointerstitial damage (T) 2	15 (2.9)	7 (8.8)	
Drugs			
ACEi	14 (2.7)	2 (2.5)	>0.99
ARB	240 (46.4)	35 (43.8)	0.60
Statin	105 (20.3)	19 (23.8)	0.65
Steroid	13 (2.5)	4 (5.0)	0.27
Other immunosuppressants	13 (2.5)	1 (1.3)	0.71
Laboratory tests			
Serum creatinine (mg/dL)	1.2 ± 0.7	1.2 ± 0.6	0.56
Serum albumin (g/dL)	3.8 ± 0.5	3.8 ± 0.3	0.89
Fasting plasma glucose (mg/dL)	100.3 ± 20.4	112.4 ± 43.8	<0.001
Serum hemoglobin (g/dL)	12.5 ± 1.7	12.9 ± 1.9	0.04
Serum uric acid (mg/dL)	6.0 ± 1.8	6.9 ± 1.7	<0.001
Serum triglyceride (mg/dL)	165.2 ± 145.6	182.9 ± 120.3	0.32
Serum LDL-C (mg/dL)	120.8 ± 46.3	1,220.6 ± 31.9	0.98
Serum HDL-C (mg/dL)	56.7 ± 17.8	54.0 ± 21.1	0.25
C reactive protein (mg/L)	0.8 (0.3–3.3)	0.8 (0.3–1.9)	0.40
C3 (mg/dL)	114.6 ± 19.5	119.0 ± 26.2	0.19
C4 (mg/dL)	29.9 ± 9.6	37.0 ± 14.1	<0.001

(Continued to the next page)

Table 1. Continued

Characteristic	Derivation cohort	Validation cohort	p-value
IgA (mg/dL)	322.8 ± 117.7	303.9 ± 88.4	0.31
IgG (mg/dL)	1,056.4 ± 331.6	975.8 ± 310.6	0.14
IgM (mg/dL)	117.7 ± 62.8	118.3 ± 51.4	0.95
UPCR (g/gCr)	1.9 (1.4–3.0)	2.0 (1.4–3.1)	0.28
Urine RBC, per HPF	30 (10–100)	20 (5–100)	0.003
RBC dysmorphism (%)	21.7 ± 25.9	18.1 ± 19.4	0.42
Radiologic findings			
Right kidney size (cm)	10.3 ± 4.3	10.5 ± 1.0	0.68
Left kidney size (cm)	10.9 ± 1.0	10.5 ± 1.0	0.21
Chronic change	143 (27.7)	21 (26.3)	0.90
Renal cyst	66 (12.8)	11 (13.8)	0.78
Renal stone	14 (2.7)	3 (3.8)	0.46

Data are expressed as mean ± standard deviation, median (interquartile range), or number (%).

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; C3, complement component 3; C4, complement component 4; DBP, diastolic blood pressure; HDL, high-density lipoprotein cholesterol; HPF, high power field; Ig, immunoglobulin; LDL-C, low-density lipoprotein cholesterol; RBC, red blood cell; SBP, systolic blood pressure; UPCR, urine protein/creatinine ratio.